Jui-Cheng TsengJames Cheng-Chung WeiAtul DeodharRuvie MartinBrian PorterSuzanne McCreddinZsolt Talloczy2026-01-302026-01-302020-11-2610.3389/fimmu.2020.561748https://scholars.csmu.edu.tw/handle/123456789/4098<jats:sec><jats:title>Objectives</jats:title><jats:p>To present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This <jats:italic>post hoc</jats:italic> analysis reports data from Taiwanese patients originally randomized to subcutaneous secukinumab 150 or 75mg or placebo every 4 weeks (following intravenous loading dose) who were invited to enter the 3-year extension study. Assessments at Week 208 included ASAS20/40 responses and other clinically relevant endpoints. Efficacy data are presented as observed. Safety analyses included all patients who received ≥1 dose of secukinumab.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 57 Taiwanese patients in the core trial, 48 entered the extension study and 87.5% patients (42/48) completed 4 years of treatment. Thirteen Taiwanese patients (including placebo-switchers) were escalated from 75 to 150mg (approved dose) at some point starting from Week 172. ASAS20/40 responses were sustained through 4 years in the Taiwanese patients who were originally randomized to secukinumab 150mg. Clinical responses were improved in those patients who received dose-escalation from 75 to 150mg during the study. No unexpected safety signals were reported.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Secukinumab 150mg demonstrated sustained efficacy over 4 years in Taiwanese patients with active ankylosing spondylitis. The safety profile of secukinumab was consistent with previous reports.</jats:p></jats:sec><jats:sec><jats:title>ClinicalTrials.gov identifier</jats:title><jats:p>NCT01863732.</jats:p></jats:sec>[SDGs]SDG3journal-article